MENU
+Compare
OTLK
Stock ticker: NASDAQ
AS OF
Apr 4, 12:48 PM (EDT)
Price
$1.16
Change
-$0.05 (-4.13%)
Capitalization
38.74M

OTLK Outlook Therapeutics Forecast, Technical & Fundamental Analysis

Outlook Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications... Show more

Industry: #Biotechnology
OTLK
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I.Advisor
a Summary for OTLK with price predictions
Apr 03, 2025

OTLK in upward trend: price expected to rise as it breaks its lower Bollinger Band on March 31, 2025

OTLK may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In of 34 cases where OTLK's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where OTLK's RSI Oscillator exited the oversold zone, of 20 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 4 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where OTLK advanced for three days, in of 252 cases, the price rose further within the following month. The odds of a continued upward trend are .

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on March 25, 2025. You may want to consider selling the stock, shorting the stock, or exploring put options on OTLK as a result. In of 96 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

The Moving Average Convergence Divergence Histogram (MACD) for OTLK turned negative on March 28, 2025. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 47 similar instances when the indicator turned negative. In of the 47 cases the stock turned lower in the days that followed. This puts the odds of success at .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where OTLK declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

The Aroon Indicator for OTLK entered a downward trend on April 03, 2025. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.000) is normal, around the industry mean (13.581). P/E Ratio (0.000) is within average values for comparable stocks, (64.662). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.879). Dividend Yield (0.000) settles around the average of (0.025) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (248.206).

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating slightly worse than average price growth. OTLK’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. OTLK’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.

View a ticker or compare two or three
OTLK
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I. Advisor
published Earnings

OTLK is expected to report earnings to rise 22.92% to -98 cents per share on May 15

Outlook Therapeutics OTLK Stock Earnings Reports
Q1'24
Est.
$-0.98
Q4'23
Beat
by $0.19
Q3'23
Missed
by $0.94
Q2'23
Missed
by $1.55
Q1'23
Missed
by $0.54
The last earnings report on February 14 showed earnings per share of -80 cents, beating the estimate of -99 cents. With 151.71K shares outstanding, the current market capitalization sits at 38.74M.
A.I. Advisor
published General Information

General Information

a manufacturer of biosimilar versions of biopharmaceuticals

Industry Biotechnology

Profile
Fundamentals
Details
Industry
Biotechnology
Address
485 Route 1 South Building F
Phone
+1 609 619-3990
Employees
24
Web
https://www.outlooktherapeutics.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
OMCL34.04-1.42
-4.00%
Omnicell
CSX27.99-1.75
-5.88%
CSX Corp
HBCP41.99-3.10
-6.88%
Home Bancorp
ECOR5.87-0.75
-11.33%
electroCore
AEO10.44-2.21
-17.47%
American Eagle Outfitters

OTLK and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, OTLK has been loosely correlated with HEPA. These tickers have moved in lockstep 34% of the time. This A.I.-generated data suggests there is some statistical probability that if OTLK jumps, then HEPA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To OTLK
1D Price
Change %
OTLK100%
-3.20%
HEPA - OTLK
34%
Loosely correlated
+1.21%
CYTK - OTLK
33%
Loosely correlated
+0.67%
PDSB - OTLK
33%
Loosely correlated
-9.09%
MCRB - OTLK
32%
Poorly correlated
+1.42%
VIR - OTLK
31%
Poorly correlated
-8.02%
More